Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Research & Development (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Research & Development for 11 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 32.42% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.7 million, a 34.05% increase, with the full-year FY2024 number at $13.5 million, up 29.29% from a year prior.
  • Research & Development was $2.3 million for Q3 2025 at Marker Therapeutics, down from $4.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.0 million in Q4 2021 to a low of -$3.8 million in Q3 2022.
  • A 5-year average of $3.7 million and a median of $3.1 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 155.94% in 2022, then skyrocketed 153.88% in 2023.
  • Marker Therapeutics' Research & Development stood at $8.0 million in 2021, then crashed by 72.78% to $2.2 million in 2022, then rose by 19.93% to $2.6 million in 2023, then soared by 94.33% to $5.1 million in 2024, then plummeted by 53.88% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Research & Development are $2.3 million (Q3 2025), $4.2 million (Q2 2025), and $3.1 million (Q1 2025).